MissionIR Articles
-
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) and Its Collaborators Are Positioned to Rapidly Develop COVID-19 Treatments to Neutralize Emerging Variants
The Food and Drug Administration (“FDA”) has, over the last two years, authorized several drugs as treatments for mild-to-moderate COVID-19 or as pre-exposure prophylaxis (“PrEP”) for the prevention of the disease. Most of these drugs…
-
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) NanoAb Product Shows Preclinical Promise as COVID Preventative for consumers Hit by Evusheld’s EUA Withdrawal
Pioneering immunotherapy developer BiondVax Pharmaceuticals (NASDAQ: BVXV) is seeing convincingly positive outcomes for preventing and arresting disease in COVID patients during an ongoing preclinical in vivo study, even as continually evolving variants of the COVID…
-
MissionIRNewsBreaks – BiondVax Pharmaceuticals Ltd.’s (NASDAQ: BVXV) Lead NanoAb Candidate Demonstrates Significant Advantages
BiondVax (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, recently achieved key milestones. These include the demonstration of statistically significant…
-
BiondVax Pharmaceuticals Ltd.’s (NASDAQ: BVXV) COVID-19 NanoAb Takes Centerstage at the 2023 BIO CEO & Investor Conference
BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products mainly for treating infectious and autoimmune diseases, took part in the 2023 BIO CEO & Investor Conference held at…
-
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Encouraged by Nanosized Antibody Study Results as Market Forecasts Predict Rapid Growth
Immunotherapeutic product innovator BiondVax Pharmaceuticals (NASDAQ: BVXV) is focused on developing, manufacturing, and commercializing innovative nanosized antibodies (NanoAbs) for the treatment of infectious diseases and autoimmune diseases, stepping up its pursuit of disrupting the monoclonal…
-
MissionIRNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Animal Study Results Featured in Aegis Capital Corp. Updated Price Target
BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotech company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, is the subject of an updated report released from Aegis…
-
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Aiming to Capture Significant Market Share for Treatment and Prevention of COVID-19 Illness with Innovative Inhaled NanoAb
The Food and Drug Administration (“FDA”) recently withdrew the authorization of AstraZeneca PLC (NASDAQ: AZN)’s Evusheld, a combination of two monoclonal antibodies (“mAbs”), which was being marketed as a pre-exposure prophylaxis to prevent COVID-19 infection…
-
MissionIRNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) to Present at BIO CEO & Investor Conference
BiondVax (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, today announced that its CEO Amir Reichman will present at the…
-
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Reports Promising Prophylactic Results from Preclinical Proof-of-Concept NanoAb COVID-19 Study
Focused on the development, manufacture, and commercialization of innovative NanoAb immunotherapeutic products, BiondVax Pharmaceuticals (NASDAQ: BVXV) recently announced additional results in the company’s preclinical proof-of-concept study of its inhaled nanosized VHH-antibody (NanoAb) COVID-19 drug (https://ibn.fm/Kz8W4).…
-
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Developing Innovative Inhaled NanoAb Therapeutics for Multiple Indications, Including COVID-19
According to a new study, new COVID-19 subvariants have become dominant in recent months, rendering some current vaccines and treatments less effective, which could results in a surge of breakthrough infections. To date, the BQ.1,…
-
MissionIRNewsBreaks – BiondVax Pharmaceuticals Ltd.’s (NASDAQ: BVXV) NanoAb May Serve as Therapeutic and Prophylactic as Shown in Preclinical Study
BiondVax (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, today announced additional results in a preclinical proof-of-concept study of its…
-
BiondVax Pharmaceuticals Ltd.’s (NASDAQ: BVXV) Preclinical Study on Inhaled NanoAb COVID-19 Therapy Shows Elimination of Virus from Lungs
Mainland China is experiencing a fresh wave of COVID-19 infections sweeping some of its most populous provinces. The SARS-CoV-2 virus, which causes COVID-19, has been spreading fast since the Chinese government in early December lifted…
-
MissionIRNewsBreaks – BiondVax Pharmaceuticals Ltd.’s (NASDAQ: BVXV) NanoAb Pipeline Targeting Large Underserved Medical Needs
BiondVax (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, recently announced statistically significant (p<0.001) efficacy results in a preclinical in-vivo…
-
MissionIRNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Releases Study Results Indicating Inhaled COVID-19 Therapy Virtually Eliminated SARS-COV-2 Virus
BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotech company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, is reporting additional results from a preclinical in vivo proof-of-concept…
-
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Receives $57 Share Valuation on Potential of NanoAb Platform
Calendar year 2022 has been eventful for BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious diseases and autoimmune diseases. Recently, the…
-
MissionIRNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Announces Participation in Upcoming Biotech Showcase
BiondVax Pharmaceuticals (NASDAQ: BVXV) CEO Amir Reichman will be presenting at the Biotech Showcase Conference, scheduled for Jan. 9–11, 2023. The conference is being held in San Francisco during the J.P. Morgan 41st annual Healthcare…
-
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Releases Business Updates and Announces CEO’s Upcoming Speaking Engagements
BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotechnology company focused on the development, manufacturing, and commercialization of innovative immunotherapeutic products used primarily for the treatment of infectious and autoimmune diseases, recently released key financials for the quarter…
-
MissionIRNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Releases Letter to Shareholders
BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotech company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, has published a letter from CEO Amir Reichman. The letter…
-
MissionIRNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Well-Positioned to Bring Innovative Therapies to Market
BiondVax (NASDAQ: BVXV) is focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases. “BiondVax is developing a pipeline of nanosized antibody (‘NanoAb’) therapies addressing diseases underserved…
-
MissionIRNewsBreaks – Aegis Capital Corp. Acted as Sole Bookrunner on BiondVax Pharmaceuticals Ltd.’s (NASDAQ: BVXV) $8M Underwritten Public Offering
BiondVax (NASDAQ: BVXV) is a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases. Aegis Capital Corp., which is dedicated to providing corporate finance,…
Search Articles
Latest Articles
- MissionIRNewsBreaks – Versus Systems Inc. (NASDAQ: VS) Renews Texas Rangers Partnership For Filter Fan Cam Through 2026 Season
- MissionIRNewsBreaks – TYTL Corp Closes Seed Funding Round, Announces Partnerships With Beeline Holdings (NASDAQ: BLNE) And Anchorage Digital
- MissionIRNewsBreaks – Voyager Acquisition Corporation (NASDAQ: “VACHU,” “VACH,” “VACHW”) Reports 99.67% Share Redemptions Ahead Of VERAXA Biotech Merger
- NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Appoints TMS, Neuroplasticity Researcher Joshua Brown MD, PhD, as Chief Medical Innovation Officer
- MissionIRNewsBreaks – Datavault AI Inc. (NASDAQ: DVLT) CEO Nate Bradley To Present Tokenized Legacy Platform At Luminary 2026 During Oscars Weekend